Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | MMP2 | P08253 | 2/20 | 0.67 |
| ▸ | CA1 | P00915 | 1/20 | 0.67 |
| ▸ | MMP1 | P03956 | 1/20 | 0.67 |
| ▸ | MMP9 | P14780 | 1/20 | 0.67 |
| ▸ | MMP8 | P22894 | 1/20 | 0.67 |
| ▸ | MMP13 | P45452 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | FLT1 | P17948 | 3/20 | 0.62 |
| ▸ | FLT4 | P35916 | 3/20 | 0.62 |
| ▸ | KDR | P35968 | 3/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | DDX3X | O00571 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8304862 | 0.92 | GAA (0.76) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL5744336 | 0.88 | CA2 (0.62) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL5742827 | 0.88 | FLT1 (0.74) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL5744605 | 0.88 | CA2 (0.62) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL8661710 | 0.85 | FLT1 (0.74) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL5742900 | 0.85 | CA2 (0.62) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL8654939 | 0.84 | FLT1 (0.76) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL5744476 | 0.82 | FLT1 (0.78) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL8548451 | 0.81 | CA2 (0.68) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL6642132 | 0.81 | GAA (0.62) | GAAFLT1FLT4KDRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | ASIA VISION LIMITED (CN) | 2024-07-18 | — | — | US | claimed |
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | ASIA VISION LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
| EP-4199924-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2023-06-28 | — | — | EP | disclosed |
| CN-114073703-B | Compositions and methods for treating nonalcoholic steatohepatitis | 苏州亚盛药业有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-110483501-B | N- (phenylsulfonyl) benzamides and related compounds as BCL-2 inhibitors | 密歇根大学董事会 | 2022-07-01 | — | — | CN | disclosed |
| WO-2022037684-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022037683-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-02-24 | — | — | WO | disclosed |
| CN-114073703-A | Compositions and methods for treating nonalcoholic steatohepatitis | 苏州亚盛药业有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-114073707-A | Compositions and methods for treating systemic lupus erythematosus | 苏州亚盛药业有限公司 | 2022-02-22 | — | — | CN | disclosed |
| US-7402696-B2 | Benzene compounds | AJINOMOTO CO., INC. (JP) | 2008-07-22 | — | — | US | disclosed |
| US-20070105899-A1 | Benzene compounds | AJINOMOTO CO., INC. (JP) | 2007-05-10 | — | — | US | disclosed |
| WO-2005049593-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
| US-5360802-A | Antagonists of cholecystokinin and gastrin | MERCK SHARPE & DOHME LTD. | 1994-11-01 | — | — | US | disclosed |
| EP-0514133-A1 | Benzodiazepine derivatives, compositions containing them and their use in therapy | MERCK SHARP & DOHME LTD. (GB) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | BCL2, BCL2L2, BCL2L1 | CA2 2456/4885MMP2 987/4885CA1 2979/4885 |
| US-20070105899-A1 | Benzene compounds | ACACB, ACACA, FABP4 | CA2 4533/4885MMP2 1538/4885CA1 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.